Searched for
GLENMARK EBITDA GROWTH
Glenmark Q3 profit rises 16% on strong India, US performanceGlenmark Pharmaceuticals posted 16% growth in December-quarter profit on strong India formulations demand, improved North America performan...- Glenmark Pharma shares in focus as Q1 profit slumps 86% YoYGlenmark Pharma reported an 86% YoY drop in Q1FY26 net profit to Rs 46.9 crore, even as revenue stayed flat at Rs 3,264 crore. EBITDA slipp...
- I-Sec maintains Reduce call on Glenmark Pharma, raises target price to Rs 1,300ICICI Securities maintains a Reduce call on Glenmark Pharmaceuticals, revising the target price to Rs 1,300. The brokerage anticipates reve...
- Reduce Glenmark Pharmaceuticals, target price Rs 1,265: ICICI SecuritiesICICI Securities maintains a Reduce call on Glenmark Pharmaceuticals with a target price of Rs 1,265. The current market price is Rs 1365.9...
- Glenmark Pharma shares in focus as company swings back to profit in Q3Glenmark Pharmaceuticals reported a net profit of Rs 348 crore for Q3FY25, a significant turnaround from a Rs 351 crore loss in the previou...
- Q3 results today: RVNL, Glenmark among 696 companies to announce earnings on FridayKey companies announcing their third quarter results include Samvardhana Motherson, RVNL, Glenmark, Swan Energy, and Zen Tech. Samvardhana ...
- Glenmark Pharma shares in focus after 34% stake acquisition in O2 renewable energy XXIVThe acquisition supports Glenmark’s goal of achieving carbon neutrality by 2030. The deal follows a Securities Subscription & Shareholder’s...
- Buy Glenmark Pharmaceuticals, target price Rs 1,779: Choice Equity BrokingChoice Equity Broking has issued a buy call for Glenmark Pharmaceuticals, setting a target price of Rs 1,779. The brokerage projects robust...
- Glenmark Pharma Q2 Results: Co posts Rs 355 crore net profit on robust sales growthGlenmark Pharma reported Rs 340 crore net profit in Q2FY25 led by robust sales growth in India and Europe. The drugmaker reported a net los...
- Glenmark Q1 Results: Net profit doubles to Rs 340 croreGlenmark Pharma net profit doubled to Rs 340 crore crore in Q1FY25 led by robust sales growth in India and Europe and reduction in finance,...
- Glenmark Pharma Q4 Results: Net loss widens to Rs 121 crore YoYGlenmark Pharma Q4 Results: The rise in loss was on account of declining sales in the US and exceptional items. It had reported a net loss ...
- Glenmark reports Rs 403 crore loss in Q4FY23For the fourth quarter of FY23, Glenmark’s consolidated revenue was at Rs. 3374 crore as against Rs.3019 crore in the same quarter of previ...
- Glenmark Q3 Results: Net profit jumps 21% YoY to Rs 291 croreIndia Business grew by 6.7% YoY to Rs. 1075 crore. North America revenues grew by 10.6% to Rs. 837 crore.Glenmark's Europe revenues rose 29...
- Glenmark Q2 Results: Net profit rises 1.4% YoY to Rs 278 croreRevenues rose 7.2% YoY to Rs 3,375 crore during Q2FY23 as against Rs 3,147 crore in Q2FY22
- Glenmark Life IPO attractively pricedWith a portfolio of 120 molecules, GLS is a leading developer of select high-value, non-commoditised APIs in chronic therapies. It earns on...
- Glenmark Pharma posts 3.5% rise in net profit in Q2The firm's total revenue rose 16.48% to Rs2,224.1 crore from Rs1,909.4 crore during the second quarter in the previous fiscal
- Underperform on Glenmark with a target at Rs 900: CLSAWeak free cash flows (FCF) a concern while balance sheet improvement only in 1HFY18. Going forward, improvement hinges on successful Zetia ...
- Pharma companies like Sun Pharma, Dr Reddy's likely to post 15% profit growth in Q3 FY'14Pharmaceutical companies are expected to post core profit growth of over 15 per cent, year-on-year, for the quarter ended December 2013.
- Glenmark may touch Rs 600: JP MorganJP Morgan has maintained its ‘Overweight’ rating on Glenmark Pharmaceuticals with a target price of Rs 600.
- Brokers’ Call: Glenmark, Jet AirwaysBank of America-Merrill Lynch has maintained a ‘Buy’ rating on Glenmark Pharma with a target price of Rs 475.
Load More
